Guggenheim Maintains Buy on Axsome Therapeutics, Lowers Price Target to $250
Benzinga Newsdesk 8 hours ago
Analyst RatingsNewsPrice Target
Guggenheim analyst Yatin Suneja maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and lowers the price target from $275 to $250.
Guggenheim analyst Yatin Suneja maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and lowers the price target from $275 to $250.